Back to Search
Start Over
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination:Results of the UCARE COVAC-CU study
- Source :
- Kocatürk , E , Salameh , P , Sarac , E , Vera Ayala , C E , Thomsen , S F , Zuberbier , T , Ensina , L F , Popov , T A , van Doorn , M B A , Giménez-Arnau , A M , Asero , R , Criado , P R , Aarestrup , F M , AbdulHameed Ansari , Z , Al Abri , S , Al Ahmad , M , Al Hinai , B , Allenova , A , Al-Nesf , M , Altrichter , S , Arnaout , R , Bartosińska , J , Bauer , A , Bernstein , J A , Bizjak , M , Bonnekoh , H , Bouillet , L , Brzoza , Z , Calvalcanti Dela Bianca Melo , A C , Campinhos , F L , Carne , E , Purayil , S C , Cherrez-Ojeda , I , Chong-Neto , H J , Christoff , G , Conlon , N , Jardim Criado , R F , Cvenkel , K , Damadoglu , E , Danilycheva , I , Day , C , de Montjoye , L , Demir , S , Ferucci , S M , Fomina , D , Fukunaga , A , Garcia , E , Gelincik , A , Göbel , J H , Godse , K , Gonçalo , M , Gotua , M , Grattan , C , Gugala , A , Guillet , C , Kalyoncu , A F , Karakaya , G , Kasperska-Zając , A , Katelaris , C H , Khoshkhui , M , Kleinheinz , A , Kolacinska-Flont , M , Kolkhir , P , Košnik , M , Krasowska , D , Kumaran , M S , Kuprys-Lipinska , I , Kurowski , M , Kuznetsova , E V , Larenas-Linnemann , D , Lebedkina , M S , Lee , Y , Makris , M P , Gómez , R M , Nasr , I , Neisinger , S , Oda , Y , Kara , R Ö , Palitot , E B , Papapostolou , N , Salvador Parisi , C A , Pesque , D , Peter , J , Petkova , E , Ridge , K , Rudenko , M , Rutkowski , K , Saini , S S , Salman , A , Sanchez , J , Şekerel , B , Serdotetskova , S A , Serpa , F S , Dikicier , B S , Sidiropoulos , N , Sikora , A , Sørensen , J A , Soria , A , Kucuk , O S , Thalappil , S R , Tomaszewska , K , Tuncay , G , Unal , D , Valle , S , van Lindonk , E , Vestergaard , C , Vitchuk , A , Xepapadaki , P , Ye , Y M , Zalewska-Janowska , A , Zamlynski , M & Maurer , M 2023 , ' Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination : Results of the UCARE COVAC-CU study ' , Journal of Allergy and Clinical Immunology , vol. 152 , no. 5 , pp. 1095
- Publication Year :
- 2023
-
Abstract
- Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination lead
Details
- Database :
- OAIster
- Journal :
- Kocatürk , E , Salameh , P , Sarac , E , Vera Ayala , C E , Thomsen , S F , Zuberbier , T , Ensina , L F , Popov , T A , van Doorn , M B A , Giménez-Arnau , A M , Asero , R , Criado , P R , Aarestrup , F M , AbdulHameed Ansari , Z , Al Abri , S , Al Ahmad , M , Al Hinai , B , Allenova , A , Al-Nesf , M , Altrichter , S , Arnaout , R , Bartosińska , J , Bauer , A , Bernstein , J A , Bizjak , M , Bonnekoh , H , Bouillet , L , Brzoza , Z , Calvalcanti Dela Bianca Melo , A C , Campinhos , F L , Carne , E , Purayil , S C , Cherrez-Ojeda , I , Chong-Neto , H J , Christoff , G , Conlon , N , Jardim Criado , R F , Cvenkel , K , Damadoglu , E , Danilycheva , I , Day , C , de Montjoye , L , Demir , S , Ferucci , S M , Fomina , D , Fukunaga , A , Garcia , E , Gelincik , A , Göbel , J H , Godse , K , Gonçalo , M , Gotua , M , Grattan , C , Gugala , A , Guillet , C , Kalyoncu , A F , Karakaya , G , Kasperska-Zając , A , Katelaris , C H , Khoshkhui , M , Kleinheinz , A , Kolacinska-Flont , M , Kolkhir , P , Košnik , M , Krasowska , D , Kumaran , M S , Kuprys-Lipinska , I , Kurowski , M , Kuznetsova , E V , Larenas-Linnemann , D , Lebedkina , M S , Lee , Y , Makris , M P , Gómez , R M , Nasr , I , Neisinger , S , Oda , Y , Kara , R Ö , Palitot , E B , Papapostolou , N , Salvador Parisi , C A , Pesque , D , Peter , J , Petkova , E , Ridge , K , Rudenko , M , Rutkowski , K , Saini , S S , Salman , A , Sanchez , J , Şekerel , B , Serdotetskova , S A , Serpa , F S , Dikicier , B S , Sidiropoulos , N , Sikora , A , Sørensen , J A , Soria , A , Kucuk , O S , Thalappil , S R , Tomaszewska , K , Tuncay , G , Unal , D , Valle , S , van Lindonk , E , Vestergaard , C , Vitchuk , A , Xepapadaki , P , Ye , Y M , Zalewska-Janowska , A , Zamlynski , M & Maurer , M 2023 , ' Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination : Results of the UCARE COVAC-CU study ' , Journal of Allergy and Clinical Immunology , vol. 152 , no. 5 , pp. 1095
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1439549088
- Document Type :
- Electronic Resource